Prademagene zamikeracel

Brand names: Zevaskyn · Active ingredient: Prademagene Zamikeracel

In short: ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Forms & strengthsZEVASKYN is supplied as single-dose cellular sheets each measuring 41.25 cm2 (5.5 cm x 7.5 cm) and consisting of patient's own viable, gene-modified cells that contain functional copies of the COL7A1 gene, which express collagen 7 (C7) protein. …
LabelAbeona Therapeutics Inc.
Label updatedJun 18, 2026

What is Prademagene zamikeracel used for?

ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Prademagene zamikeracel dosage

For autologous

topical application

on wounds

only.

The recommended dose of ZEVASKYN is based on the surface area of the wound(s).

One sheet of ZEVASKYN covers an area of 41.25 cm2.

Up to twelve ZEVASKYN sheets may be manufactured from the patient biopsies and supplied for potential use.

Receipt of ZEVASKYN

ZEVASKYN is shipped directly to the qualified treatment center sealed in transport packaging.

If the patient is expected to be ready for same-day application, transport the packaging to the operating room. Hold at room temperature (15-25°C) until preparation to maintain cell viability.

If the patient is not expected to be ready for same-day application, store the packaging containing ZEVASKYN in a secure onsite location at room temperature (15-25°C) until preparation to maintain cell viability.

Preparation

ZEVASKYN is to be prepared by the manufacturer in an appropriate healthcare setting for surgical application by a qualified healthcare provider.

Manufacturer will conduct Quality Control (QC) testing to release the product immediately prior to surgery in the operating room.

Verify patient’s identity during preparation.

Hold ZEVASKYN at room temperature (15-25°C) until application.

Apply all selected sheets in a single surgical session.

Below is the list of standard surgical supplies needed for ZEVASKYN administration and not provided by the manufacturer:

scalpel

scissors

forceps

resorbable sutures

non-adhesive dressings

topical antibiotic ointment

1. Verify patient’s identity prior to ZEVASKYN application. Do not apply ZEVASKYN if the information on the patient-specific label(s) does not match the intended patient.

2. Prepare wound by debridement under general or other appropriate anesthesia to accommodate ZEVASKYN sheet(s).

3. Before surgical application, pick up ZEVASKYN sheet with forceps by grasping the titanium ligating clips (Figure 1). Handle ZEVASKYN sheets only with forceps and only by the titanium ligating clips.

Figure 1. ZEVASKYN sheets removed with forceps for application

4. Do not trim ZEVASKYN sheets.

5. Apply unaltered ZEVASKYN sheets onto the wound bed only (nylon suture on the ZEVASKYN sheet facing away from wound) by affixing via resorbable sutures. Do not suture ZEVASKYN onto healthy intact skin. Do not overlap ZEVASKYN sheets on wounds.

6. Apply all selected sheets in a single surgical session.

7. Cover area of application of ZEVASKYN sheets with non-adhesive dressings and topical antibiotic ointment.

After ZEVASKYN application

8. Instruct patient to leave the treated area undisturbed for 5-10 days at the discretion of the physician based on individual needs for immobilization of treated areas and post-surgical recovery.

9. …

How to take Prademagene zamikeracel — instructions & advice from the label

Discuss the following with patients and/or caregivers.

Hyp

ersensitivity Reactions: Inform patients and/or caregivers that hypersensitivity reactions may occur with ZEVASKYN application. Advise patients and/or caregivers to seek immediate medical evaluation if any signs and symptoms of hypersensitivity reaction occur, such as itching, swelling, hives, difficulty breathing, runny nose, watery eyes, nausea, and in severe cases, anaphylaxis .

Insertional Oncogenesis: Inform patients and/or caregivers about the possible risk of insertional oncogenesis and development of malignancies with ZEVASKYN application .

Transmission of

Infectious Agents: Inform patients and/or caregivers about the possible risk of transmission of infectious agents with ZEVASKYN application

.

Post

-application care:

Expect pain and itching at the treatment site during the healing process. Contact the treating physician if experiencing fever, increased drainage, worsening pain and/or swelling or any other adverse effect at or around the treatment site .

Do not disturb the surgical dressing covering the ZEVASKYN epidermal sheet for 5-10 days. …

Warnings & precautions

Do not take this medicine if: None.

Severe hypersensitivity reactions to vancomycin, amikacin, or product excipients may occur with ZEVASKYN application. Monitor for signs and symptoms of hypersensitivity reactions such as itching, swelling, hives, difficulty breathing, runny nose, watery eyes, nausea, and in severe cases, anaphylaxis and treat according to standard clinical practice.

RVV-mediated insertional oncogenesis may potentially occur after treatment with ZEVASKYN . Monitor patients lifelong after treatment with ZEVASKYN for the development of malignancies. In the event that a malignancy occurs, contact Abeona Therapeutics Inc. at 1-844-888-2236 to obtain instructions on collecting patient samples for testing.

Transmission of infectious disease or agents may occur with ZEVASKYN administration because it is manufactured using human and bovine-derived reagents, which are tested for human and animal viruses, bacteria, fungi, and mycoplasma before use. These measures do not eliminate the risk of transmitting these or other infectious diseases or agents.

Prademagene zamikeracel side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a product cannot be directly compared to the rates in the clinical trials of another product and may not reflect the rates observed in practice.

The safety data described in this section reflects exposure of 11 patients to ZEVASKYN in the VIITAL study .

The median number of sheets patients received was 6 (range 3-6), and the total exposure time was 6 months following ZEVASKYN application.

The most common adverse reactions occurring in ≥5% of patients were procedural pain (n=3; 27%) and pruritus (n=1; 9%).

About this medicine

ZEVASKYN is composed of autologous cells isolated from skin punch biopsies of patients with mutations in the collagen type VII alpha 1 chain

(

C

OL

7A1

) gene and which have been transduced ex vivo with a replication-incompetent retroviral vector (RVV) containing the full-length COL7A1 gene. The resulting gene-modified cell sheets express functional collagen VII (C7) protein. ZEVASKYN is manufactured using human- and animal-derived reagents.

ZEVASKYN is provided as cellular sheets of 41.25 cm2 (5.5 cm x 7.5 cm) secured to sterile petrolatum gauze using sterile ligation titanium clips for surgical application. The cellular sheets consist of autologous, viable, gene-modified cells. Up to twelve (12) sheets may be manufactured from the patient biopsies and supplied for potential use.

Each ZEVASKYN sheet is packaged in a clamshell and sealed transport pouch containing sterile transport media. The transport media includes reagents derived from human and animal materials, including bovine pituitary extract, bovine transferrin, and human transferrin. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f8782480-8782-4748-9764-b9ed60979d47. Read the full official label on DailyMed.